story of the week
Abemaciclib + Trastuzumab ± Fulvestrant vs Trastuzumab + Standard-of-Care Chemotherapy in HR+, HER2+ Advanced Breast Cancer
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
The Lancet Oncology
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Abemaciclib Plus Trastuzumab With or Without Fulvestrant Versus Trastuzumab Plus Standard-of-Care Chemotherapy in Women With Hormone Receptor-Positive, HER2-Positive Advanced Breast Cancer (monarcHER): A Randomised, Open-Label, Phase 2 Trial
Lancet Oncol 2020 Apr 27;[EPub Ahead of Print], SM Tolaney, AM Wardley, S Zambelli, JF Hilton, TA Troso-Sandoval, F Ricci, SA Im, SB Kim, SR Johnston, A Chan, S Goel, K Catron, SC Chapman, GL Price, Z Yang, MC Gainford, F AndréFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.